ArticleBMC cancer2025
Comprehensive analysis of gene expression alterations in breast cancer patients via PKCθ-TBK1-mTORC1 signaling pathway.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer remains a leading cause of cancer-related mortality among women globally. The emergence of chemoresistance and the lack of early detection tools necessitate the identification of reliable molecular biomarkers and therapeutic targets. Protein kinase C theta (PRKCQ/PKCθ), a serine/threonine kinase, has been implicated in immune signaling and cancer. The current study was designed to investigate the relative expression levels of PRKCQ and its downstream components, including TANK-binding kinase 1 (TBK1), mammalian target of rapamycin (mTORC1), ribosomal S6 kinase (S6K), Jun Proto-Oncogene (JUNB), and the tumor suppressor gene p21, in breast cancer. The study also aimed to evaluate their association with key clinicopathological features.
methodsGene expression analysis was conducted using quantitative real-time PCR (qRT-PCR) on breast cancer blood samples. Expression levels were compared between breast cancer patients and healthy controls, and further analyzed to metastasis, cancer stage, histological subtype, molecular classification, family history, BRCA status, menopausal status, and lactation history.
resultsExpression of PRKCQ, TBK1, mTORC1, S6K, and JUNB was significantly upregulated in breast cancer blood samples compared to controls, whereas p21 expression was downregulated. Statistically significant associations were observed between gene expression levels and various clinicopathological parameters. Notably, PRKCQ showed strong differential expression across molecular subtypes with the highest expression in TNBC. A signaling axis involving PRKCQ-TBK1-mTORC1-S6K and an independent PRKCQ-JUNB-VEGFR axis was proposed.
conclusionThe relative expression of PRKCQ and its associated signaling components suggests their critical role in breast cancer progression. These molecules, especially PRKCQ, may serve as potential biomarkers for early detection and prognosis, as well as targets for therapeutic intervention following further validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.